Skip to main content
$2.65 +0.14 (+5.58%) At close · Jul 30
Market Cap
$28.37M
Shares
11.30M

Lantern Pharma Inc. Earnings Call Transcripts

Every quarterly earnings call for Lantern Pharma Inc. (LTRN) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Earnings call
FY25 · Q4
2026-03-30
Lantern Pharma Inc. Q4 FY2025 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-13
Lantern Pharma Inc. Q3 FY2025 Earnings Call
Confident tone LP-184 Phase Ia Clinical Results LP-284 Non-Hodgkin's Lymphoma Program Pipeline Expansion and Indications
Diluted EPS
$-0.39
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-13
Lantern Pharma Inc. Q2 FY2025 Earnings Call
Diluted EPS
$-0.40
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-15
Lantern Pharma Inc. Q1 FY2025 Earnings Call
Confident tone Clinical pipeline progress AI platform (RADR) commercialization HARMONIC trial geographic expansion (Asia)
Diluted EPS
$-0.42
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-27
Lantern Pharma Inc. Q4 FY2024 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Lantern Pharma Inc. Q3 FY2024 Earnings Call
Confident tone LP-184 / LP-284 synthetic lethal programs Starlight Therapeutics / CNS oncology (GBM) LP-300 / Harmonic trial in never-smoker NSCLC
Diluted EPS
$-0.42
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Lantern Pharma Inc. Q2 FY2024 Earnings Call
Diluted EPS
$-0.46
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-29
Lantern Pharma Inc. Q1 FY2024 Earnings Call
Confident tone Starlight subsidiary and STAR-001 in brain cancer LP-184 clinical progress in DDR-deficient tumors AI platform RADR and computational drug discovery
Diluted EPS
$-0.51
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-20
Lantern Pharma Inc. Q4 FY2023 Earnings Call
Confident tone Clinical Pipeline Progress AI Platform RADAR Starlight Therapeutics / CNS Cancers
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Lantern Pharma Inc. Q3 FY2023 Earnings Call
Diluted EPS
$-0.29
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Lantern Pharma Inc. Q2 FY2023 Earnings Call
Diluted EPS
$-0.44
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Lantern Pharma Inc. Q1 FY2023 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-20
Lantern Pharma Inc. Q4 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-07
Lantern Pharma Inc. Q3 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Lantern Pharma Inc. Q2 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Lantern Pharma Inc. Q1 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-10
Lantern Pharma Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-01
Lantern Pharma Inc. Q3 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Lantern Pharma Inc. Q2 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-03
Lantern Pharma Inc. Q1 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-10
Lantern Pharma Inc. Q4 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-10-29
Lantern Pharma Inc. Q3 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-24
Lantern Pharma Inc. Q2 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Showing 1–23 of 23 earnings calls
Key facts CIK 1763950 CUSIP 51654W101 13F (30d) 8 filings 8 filers Visit website Investor relations